Nuzenio

What Monte Rosa

What Monte Rosa news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 5 publisher sources 100/100 entity strength

Latest news

What Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - simplywall.stsimplywall.st · Sun, 09 Aug 2026 11:26:18 GMTMonte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 07:10:56 GMTMonte Rosa Therapeutics, Inc. Stock 12‑Month Price Target Cut to $30.33, Implies 94% Upside - TradingViewTradingView · Thu, 06 Aug 2026 20:23:17 GMTMonte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 13:50:06 GMTZacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to "Hold" - MarketBeatMarketBeat · Thu, 06 Aug 2026 12:11:30 GMTMonte Rosa Therapeutics Q2 2026: Revenue $9M, EPS $(0.43) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 11:11:00 GMTMonte Rosa Therapeutics (NASDAQ: GLUE) posts 2026 net loss on revenue drop - Stock TitanStock Titan · Thu, 06 Aug 2026 11:09:55 GMTMonte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 11:00:00 GMT

Timeline

Sun, 09 Aug 2026 11:26:18 GMTWhat Monte Rosa Therapeutics (GLUE)'s Swing From Profit To Deeper Losses Means For Shareholders - simplywall.st
Fri, 07 Aug 2026 07:10:56 GMTMonte Rosa Therapeutics (GLUE) Is Down 30.7% After Deepening Q2 Losses And H1 Earnings Reversal - Yahoo Finance
Thu, 06 Aug 2026 20:23:17 GMTMonte Rosa Therapeutics, Inc. Stock 12‑Month Price Target Cut to $30.33, Implies 94% Upside - TradingView
Thu, 06 Aug 2026 13:50:06 GMTMonte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Thu, 06 Aug 2026 12:11:30 GMTZacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to "Hold" - MarketBeat
Thu, 06 Aug 2026 11:11:00 GMTMonte Rosa Therapeutics Q2 2026: Revenue $9M, EPS $(0.43) — 10-Q Summary - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for What Monte Rosa.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

5 distinct publisher/source names are currently connected to this entity page.